Overview
- Genmab said the decision reflects a focus on higher‑impact opportunities and an increasingly competitive landscape.
- Resources will shift to EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan (Rina‑S), which are advancing in late‑stage studies.
- Management said the move does not change the company’s full‑year 2025 financial guidance.
- U.S.-listed shares traded about 2% lower in premarket dealing after the announcement.
- Acasunlimab is a 4‑1BB‑activating bispecific tested in solid tumors including metastatic non‑small cell lung cancer, with Genmab assuming full control after BioNTech’s 2024 exit and gaining petosemtamab via the $8 billion Merus acquisition in September.